Diagnosis and Management of Type 2 Diabetic Kidney Disease

Afkarian, 2016, Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014, JAMA, 316, 602, 10.1001/jama.2016.10924

Bailey, 2014, Chronic kidney disease in US adults with type 2 diabetes: An updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging, BMC Res Notes, 7, 415, 10.1186/1756-0500-7-415

Tuttle, 2014, Diabetic kidney disease: A report from an ADA Consensus Conference, Am J Kidney Dis, 64, 510, 10.1053/j.ajkd.2014.08.001

Bakris, 2014, Microalbuminuria as a risk predictor in diabetes: The continuing saga, Diabetes Care, 37, 867, 10.2337/dc13-1870

Adler, 2003, Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64), Kidney Int, 63, 225, 10.1046/j.1523-1755.2003.00712.x

Dwyer, 2012, Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes: Results from the DEMAND study, Cardiorenal Med, 2, 1, 10.1159/000333249

Kramer, 2003, Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus, JAMA, 289, 3273, 10.1001/jama.289.24.3273

Penno, 2011, Clinical significance of nonalbuminuric renal impairment in type 2 diabetes, J Hypertens, 29, 1802, 10.1097/HJH.0b013e3283495cd6

Thomas, 2009, Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11), Diabetes Care, 32, 1497, 10.2337/dc08-2186

Chang, 2011, Renal outcomes in patients with type 2 diabetes with or without coexisting non-diabetic renal disease, Diabetes Res Clin Pract, 92, 198, 10.1016/j.diabres.2011.01.017

Pham, 2007, Prevalence of nondiabetic renal disease in diabetic patients, Am J Nephrol, 27, 322, 10.1159/000102598

Tone, 2005, Clinical features of non-diabetic renal diseases in patients with type 2 diabetes, Diabetes Res Clin Pract, 69, 237, 10.1016/j.diabres.2005.02.009

Sharma, 2013, The modern spectrum of renal biopsy findings in patients with diabetes, Clin J Am Soc Nephrol, 8, 1718, 10.2215/CJN.02510213

2007, KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease, Am J Kidney Dis, 49, S12

2016, Standards of medical care in diabetes-2016: Summary of revisions, Diabetes Care, 39, S4

1998, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38, BMJ, 317, 703, 10.1136/bmj.317.7160.703

Ismail-Beigi, 2012, Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients, Kidney Int, 81, 586, 10.1038/ki.2011.415

Berl, 2005, Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial, J Am Soc Nephrol, 16, 2170, 10.1681/ASN.2004090763

Ruggenenti, 2004, Preventing microalbuminuria in type 2 diabetes, N Engl J Med, 351, 1941, 10.1056/NEJMoa042167

Parving, 2001, The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes, N Engl J Med, 345, 870, 10.1056/NEJMoa011489

Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161

Lewis, 2001, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, 851, 10.1056/NEJMoa011303

Mann, 2008, Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial, Lancet, 372, 547, 10.1016/S0140-6736(08)61236-2

Fried, 2013, Combined angiotensin inhibition for the treatment of diabetic nephropathy, N Engl J Med, 369, 1892, 10.1056/NEJMoa1303154

Palevsky, 2016, Incidence, severity, and outcomes of AKI associated with dual renin-angiotensin system blockade, Clin J Am Soc Nephrol, 11, 1944, 10.2215/CJN.03470316

Parving, 2008, Aliskiren combined with losartan in type 2 diabetes and nephropathy, N Engl J Med, 358, 2433, 10.1056/NEJMoa0708379

Heerspink, 2016, Renal outcomes with aliskiren in patients with type 2 diabetes: A prespecified secondary analysis of the ALTITUDE randomised controlled trial, Lancet Diabetes Endocrinol, 4, 309, 10.1016/S2213-8587(15)00469-6

1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6

Duckworth, 2009, Glucose control and vascular complications in veterans with type 2 diabetes, N Engl J Med, 360, 129, 10.1056/NEJMoa0808431

Perkovic, 2013, Intensive glucose control improves kidney outcomes in patients with type 2 diabetes, Kidney Int, 83, 517, 10.1038/ki.2012.401

Ismail-Beigi, 2010, Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial, Lancet, 376, 419, 10.1016/S0140-6736(10)60576-4

Cherney, 2014, Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus, Circulation, 129, 587, 10.1161/CIRCULATIONAHA.113.005081

Fioretto, 2016, Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment, Diabetologia, 59, 2036, 10.1007/s00125-016-4017-1

Wanner, 2016, Empagliflozin and progression of kidney disease in type 2 diabetes, N Engl J Med, 375, 323, 10.1056/NEJMoa1515920

Groop, 2013, Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction, Diabetes Care, 36, 3460, 10.2337/dc13-0323

Cornel, 2016, Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: Outcomes from TECOS, Diabetes Care, 39, 2304, 10.2337/dc16-1415

2014, Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: A secondary analysis of the Look AHEAD randomised clinical trial, Lancet Diabetes Endocrinol, 2, 801, 10.1016/S2213-8587(14)70156-1

Friedman, 2016, Is bariatric surgery an effective treatment for type II diabetic kidney disease?, Clin J Am Soc Nephrol, 11, 528, 10.2215/CJN.07670715

Chang, 2016, Bariatric surgery is associated with improvement in kidney outcomes, Kidney Int, 90, 164, 10.1016/j.kint.2016.02.039

Sasser, 2007, Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism, J Am Soc Nephrol, 18, 143, 10.1681/ASN.2006030208

de Zeeuw, 2014, The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy, J Am Soc Nephrol, 25, 1083, 10.1681/ASN.2013080830

Schievink, 2016, Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers, Eur J Prev Cardiol, 23, 758, 10.1177/2047487315598709

Bakris, 2015, Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial, JAMA, 314, 884, 10.1001/jama.2015.10081